A kit that includes an absorbent product adapted for mucosal membrane hemostasis, and instructions using the absorbent product is disclosed. The absorbent product can include a liquid permeable pouch, and at least one sheet of absorbent material within the liquid permeable pouch. The instructions can include rolling and/or folding the absorbent product, placing the rolled and/or folded absorbent product proximate the site of the bleeding, and applying pressure to the absorbent product. The instructions can also include inserting the absorbent product into a mucous membrane, such as a nostril or the vaginal canal. Methods of utilizing the absorbent product and the kit are also disclosed.

A hemostatic surface application device having a region of hemostatic foam for contact with a patient's skin where a wound exists or is created, the device includes: a release layer, the release layer in contact with a hemostatic flexible foam section, and a structural foam layer having a front side and a back side surrounding the hemostatic flexible foam layer, forming a generally central hemostatic surface exposed through the front side of the surrounding structural foam layer, and a support layer adhered to the backside of the structural foam layer.

The invention relates to a unit for hemostasis. The unit is configured to be directly applied to a bleeding wound and comprises an envelope enclosing an inner space as well as an effective amount of a hemostatic material disposed within the inner space. Furthermore, the invention relates to an arrangement of two or more such units for hemostasis, the units being coupled to each other. Moreover, the invention relates to a method for producing an arrangement of units for hemostasis. In accordance with the method, an effective amount of a hemostatic material is disposed within an interior region of a starting material, and neck regions are formed on both sides of the charge so as to form an envelope enclosing the charge.

The present invention is directed to a hemostatic patch comprising a porous substrate and at least a pair of co-reactive polymer reagents comprising at least one nucleophilic polyalkylene oxide based component and at least one electrophilic polyalkylene oxide-based on the porous substrate in a molar ratio of about 0.2 to about 0.9:1 of primary nucleophilic groups in excess to available electrophilic groups. The present invention is also directed to processes for the manufacture and use of such hemostatic patches.

The present disclosure provides a hemostatic glove device including an absorbent fabric layer having a hemostatic agent and optionally an therapeutic agent. The present disclosure also provides methods for using the hemostatic glove device for promoting hemostasis of a wound of a patient.

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.

A wound sealing powder, method of making a wound sealing powder, and method of using a wound sealing powder to reduce blood flow from a wound are provided. Specifically, the wound sealing powder utilizes a particulate powder material of an effective amount of an insoluble cation exchange material wherein the majority of the particles in the powder have particle sizes of less than approximately 48 microns.

A knit hemostatic bandage provided herein can include a continuous rayon fiber and a continuous glass fiber. The knit hemostatic bandage can have a gauge of between 10 and 30 stitches per inch. The knit hemostatic bandage can have a Young's modulus of elasticity of less than 50 MPa.

A sheet applying device, a sheet applying system, and a sheet applying method are provided. A first sheet applying system 10 mainly includes a first sheet applying device 11 and a sheet cartridge 900. The first sheet applying device 11 mainly includes a first supporter 200 and a holder 500. The first supporter 200 mainly includes a first support shaft 210a, a second support shaft 210b, a first swing mechanism 220, a support cover 211, and a handle 300. The first support shaft 210a and the second support shaft 210b have straight cylindrical bar shapes and movably extend in parallel to each other from a proximal end side of the first sheet applying system 10 toward a distal end side of the first sheet applying system 10, in other words, in a longitudinal direction of the first supporter 200.

A wound sealing powder, method of making a wound sealing powder, and method of using a wound sealing powder to reduce blood flow from a wound are provided. Specifically, the wound sealing powder utilizes a particulate powder material of an effective amount of an insoluble cation exchange material wherein the majority of the particles in the powder have particle sizes of less than approximately 48 microns.